GlassScriptPhysician profile
Frank Caliendo
NPI 1124199211
$3,034.83
in general payments reported to CMS, 2019-2025
14 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $179 · 2021: $702 · 2022: $102 · 2023: $259 · 2024: $468 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $744.48 | 2023-2025 | Hemoblast Bellows |
| Medtronic, INC. | $406.41 | 2023-2025 | Signia, Signet, Ligasure |
| Integra Lifesciences Corporation | $396.92 | 2020-2021 | |
| Intuitive Surgical, INC. | $396.02 | 2019-2022 | |
| Tei Biosciences INC | $222.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.85 | 2022-2025 | Gattex, Entyvio, Eohilia |
| Davol INC. | $176.74 | 2020-2025 | Arista |
| Biom'Up France Sas | $144.77 | 2021 | |
| Olympus America INC. | $125.00 | 2019 | |
| Abbvie INC. | $118.40 | 2019 | |
| Braintree Laboratories, INC. | $40.89 | 2022 | |
| Hologic Sales and Service, LLC | $30.68 | 2024 | Trident Specimen Radiography System, Localizer |
| Thd America, INC. | $29.98 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $13.36 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Caliendo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.